Seagen Valuation

Is SGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SGEN ($228.74) is trading above our estimate of fair value ($199.98)

Significantly Below Fair Value: SGEN is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SGEN?

Other financial metrics that can be useful for relative valuation.

SGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue18.3x
Enterprise Value/EBITDA-62.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SGEN's PS Ratio compare to its peers?

The above table shows the PS ratio for SGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.5x
MRNA Moderna
6.2x13.6%US$42.3b
BIIB Biogen
3.2x2.5%US$31.4b
GILD Gilead Sciences
3.4x2.3%US$91.0b
BNTX BioNTech
5.3x2.9%US$22.1b
SGEN Seagen
18.8x22.6%US$43.2b

Price-To-Sales vs Peers: SGEN is expensive based on its Price-To-Sales Ratio (18.8x) compared to the peer average (5.6x).


Price to Earnings Ratio vs Industry

How does SGEN's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.6%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.6%
n/an/an/a
No more companies

Price-To-Sales vs Industry: SGEN is expensive based on its Price-To-Sales Ratio (18.8x) compared to the US Biotechs industry average (11.1x).


Price to Sales Ratio vs Fair Ratio

What is SGEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SGEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio18.8x
Fair PS Ratio4.5x

Price-To-Sales vs Fair Ratio: SGEN is expensive based on its Price-To-Sales Ratio (18.8x) compared to the estimated Fair Price-To-Sales Ratio (4.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SGEN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$228.91
0%
0.1%US$229.00US$228.00n/a13
Mar ’25n/a
US$228.91
0%
0.1%US$229.00US$228.00n/a13
Feb ’25n/a
US$228.91
0%
0.1%US$229.00US$228.00n/a13
Jan ’25n/a
US$228.91
0%
0.1%US$229.00US$228.00n/a13
Dec ’24US$212.72
US$225.41
+6.0%
5.6%US$229.00US$180.00n/a14
Nov ’24US$214.37
US$225.41
+5.2%
5.6%US$229.00US$180.00n/a14
Oct ’24US$212.15
US$225.41
+6.3%
5.6%US$229.00US$180.00n/a14
Sep ’24US$207.91
US$225.41
+8.4%
5.6%US$229.00US$180.00n/a14
Aug ’24US$192.45
US$225.41
+17.1%
5.6%US$229.00US$180.00n/a14
Jul ’24US$192.46
US$225.65
+17.2%
5.4%US$229.00US$180.00n/a15
Jun ’24US$194.67
US$220.60
+13.3%
9.9%US$229.00US$153.00n/a15
May ’24US$199.16
US$220.60
+10.8%
9.9%US$229.00US$153.00n/a15
Apr ’24US$202.47
US$215.80
+6.6%
12.4%US$229.00US$153.00n/a15
Mar ’24US$178.23
US$167.90
-5.8%
11.4%US$215.00US$141.00n/a21
Feb ’24US$139.03
US$160.67
+15.6%
12.2%US$213.00US$135.00n/a21
Jan ’24US$128.51
US$164.73
+28.2%
12.9%US$213.00US$135.00n/a22
Dec ’23US$121.02
US$164.77
+36.2%
12.9%US$213.00US$135.00US$212.7222
Nov ’23US$126.69
US$168.76
+33.2%
12.4%US$213.00US$136.00US$214.3721
Oct ’23US$136.83
US$183.43
+34.1%
10.6%US$220.00US$150.00US$212.1521
Sep ’23US$155.96
US$183.05
+17.4%
10.9%US$220.00US$150.00US$207.9121
Aug ’23US$175.47
US$183.43
+4.5%
10.8%US$220.00US$150.00US$192.4521
Jul ’23US$180.11
US$168.40
-6.5%
14.2%US$220.00US$120.00US$192.4620
Jun ’23US$134.16
US$160.94
+20.0%
10.8%US$195.00US$120.00US$194.6718
May ’23US$131.01
US$160.16
+22.2%
10.4%US$191.00US$120.00US$199.1619
Apr ’23US$148.89
US$158.84
+6.7%
10.9%US$190.00US$120.00US$202.4719
Mar ’23US$129.46
US$158.84
+22.7%
10.9%US$190.00US$120.00US$178.2319

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.